

RESEARCH HIGHLIGHT

Clonal expansion shapes the human V δ 1 T cell receptor repertoire

Serena Meraviglia and Francesco Dieli

Cellular & Molecular Immunology advance online publication, 24 July 2017; doi:10.1038/cmi.2017.66

The $\gamma\delta$ cells are a unique population of T lymphocytes that combine innate-like features and adaptive-type responses and play an important role in the early host response to infections and malignancies. Different from $\alpha\beta$ T cells, $\gamma\delta$ T cells recognize a limited set of antigens, which are shared by a variety of microbial pathogens and tumor cells in a non-MHC restricted manner;¹ thus, these cells use the TCR in a manner similar to a pattern recognition receptor (PRR). Moreover, whereas $\alpha\beta$ T cells require antigen- and cytokine-driven clonal expansion, $\gamma\delta$ T cells are equipped with immediate effector functions.¹ However, the potential $\gamma\delta$ repertoire with junctional diversity is estimated at $\sim 10^{18}$, which is much greater than the $\alpha\beta$ repertoire ($\sim 10^{16}$), thus raising questions concerning the forces governing the selection of such a huge TCR repertoire during ontogeny and whether and how

the $\gamma\delta$ TCR repertoire is shaped under physiological and pathological conditions.

In a recent issue of *Nature Communication*, Davey *et al.*² used amplicon rescued multiplex (ARM)-PCR and next-generation sequencing to investigate the clonal selection of a $\gamma\delta$ TCR repertoire that was negative for the V δ 2 chain in healthy adults and in cord blood. As expected, in all individuals, the V δ 2⁻ $\gamma\delta$ T cell population was dominated by V δ 1⁺ T cells paired with diverse V γ chains and displaying a mixed terminally differentiated effector memory (CD27⁻ CD45RA⁺) or naive (CD27⁺ CD45RA⁺) phenotype.³ Strikingly, in most (70%) adult individuals, remarkably strong focusing (i.e., a reduction in diversity) of the V δ 1⁺ TCR repertoire toward a small number of individual clonotypes (≤ 10) was observed, and this effect was evident for both TCR γ and TCR δ chains. In contrast to this focused adult subgroup, markedly less focused repertoires were observed in seven individuals (30%); notably, this minority of individuals, defined as “diverse adult donors”, were primarily cytomegalovirus (CMV) seronegative and included the youngest members of the cohort, suggesting an age-dependent modification of the V δ 1⁺ TCR repertoire.

To investigate how the V δ 1⁺ TCR repertoire differed in early life, Davey *et al.*² conducted comparable TCR repertoire analyses on the V δ 1⁺ population obtained from cord blood. V δ 1⁺ cells

dominate the cord blood $\gamma\delta$ repertoire and express V δ 1 paired with diverse V γ regions. The cord blood TCR δ 1 and TCR γ CDR3 sequences were extremely unfocused, in contrast to focused the adult V δ 1 repertoires but similar to the unfocused adult samples, and comprised numerous low-frequency clonotypes, the most prevalent of which represented $< 1.30\%$ and $< 2.17\%$ of the total unique CDR3s detected for TCR γ and TCR δ , respectively (Figure 1). As expected, detailed comparisons of the CDR3 length within and between individuals indicated that in V δ 1⁺ T cells, the mean CDR3 δ 1 length was substantially greater than that of CDR3 γ (mean 54 versus 33 nucleotides); strikingly, comparisons of the ten most prevalent TCR γ and TCR δ 1 clonotypes (typically accounting for $> 50\%$ of the repertoire) from each donor revealed private sequences (e.g., present only in one individual but absent in any other individuals either at a nucleotide or amino acid level). Therefore, the V δ 1 TCR repertoire was overwhelmingly private, with different TCR clonotypes present in each individual (Figure 1), and comparison of V δ 1 repertoire data with age- and sex-matched TCR β repertoire data revealed that V δ 1, as a repertoire, was even more private than TCR β . Moreover, the most frequent clonotypes were detected in subsequent ARM analyzes conducted 12–18 months later, and in most donors, the hierarchy of prevalent clonotypes was broadly conserved in

Central Laboratory of Advanced Diagnosis and Biomedical Research (CLADIBIOR) and Department of Biopathology and Medical Biotechnologies (DIBIMED), University of Palermo, 90129 Palermo, Italy

Correspondence: Professor S Meraviglia or Professor F Dieli Central Laboratory of Advanced Diagnosis and Biomedical Research (CLADIBIOR) and Department of Biopathology and Medical Biotechnologies (DIBIMED), University of Palermo, Corso Tukory 211, Via del Vespro 129, 90129 Palermo, Italy.

E-mail: serena.meraviglia@unipa.it or francesco.dieli@unipa.it

Received: 12 June 2017; Accepted: 13 June 2017




Figure 1 The neonatal (cord blood) TCR V δ 1 repertoire is extremely unfocused and private. In most adult individuals, the V δ 1⁺ TCR repertoire is strongly focused, with up to 50% of the repertoire comprising the 10 most abundant TCR γ and TCR δ 1 clonotypes. Moreover, the V δ 1 TCR repertoire was overwhelmingly private, with different TCR clonotypes present in each individual. The nature of the forces governing the peripheral clonal selection of the human V δ 1 TCR repertoire and the role of CMV remains to be determined.

both analyses, which clearly indicated that the clonotypic expansions prevalent in the V δ 1T cell repertoire are stably maintained over time.

Thus, these findings indicate that V δ 1T cells undergo profound expansions of TCR clonotypes in the periphery from an initially completely unfocused and private repertoire, which is highly suggestive of an adaptive-type immune response.

Hence, selection of the V δ 1 TCR repertoire differs in several key aspects from that of V γ 9V δ 2T cells, which are the major $\gamma\delta$ population in peripheral blood and secondary lymphoid organs. In contrast to the V δ 1 population, the V γ 9V δ 2 TCR repertoire data from Davey and colleagues confirmed the highly restricted CDR3 lengths, including prevalent V γ 9-JP sequences of limited complexity that were common to multiple individuals, with CDR3 γ 9 lengths of 11–18 amino acids, and >50% of the CDR3 γ 9 contained a typical 14 amino acid sequence in all donors. Moreover, analysis of the 10 most frequent TCR γ and TCR δ clonotypes in V δ 2⁺ cells from each donor revealed that the CDR3 γ 9 sequences were public and constrained in length.⁴ Although CDR3 δ 2 sequences were relatively private compared with TCR γ 9, more CDR3 δ 2 sequences than CDR3 δ 1 sequences were shared between donors. Therefore, in stark contrast to V δ 1⁺ T cells but analogous to iNKT and

MAIT populations, the V γ 9V δ 2 population expresses a semi-invariant TCR.

Consistent with these data, Dimova *et al.*⁵ detected prevalent V γ 9 sequences that were present at birth in multiple individuals, regardless of pathogen exposure. These observations are consistent with a semi-invariant, innate-like biology for the V γ 9V δ 2 subset that is compatible with the polyclonal activation of these cells via phosphoantigens.

Importantly, V δ 1 clonal expansion was concomitant with phenotypic differentiation involving the loss of secondary lymphoid homing markers and the upregulation of effector molecules. The vast majority of clonal populations occurred in an effector memory/terminally differentiated CD27^{lo/neg} CD45RA⁺ population, whereas clonotypes showing naive-type CD27^{hi} CD45RA⁺ expression were diverse, suggesting that V δ 1 TCR repertoire focusing was accompanied by a transition from a naive to an effector phenotype.

Davey and colleagues used other surface markers to better define the cell differentiation state, and thus V δ 1 CD27^{hi} cells express other naive molecules, such as IL-7R α , CD28, CCR7, and CD62L, which were absent in the CD27^{lo/neg} compartment. Functional analysis showed that the naive CD27^{hi} subset proliferated in response to IL-7 stimulation, while the CD27^{lo/neg} required IL-15

for proliferation, and this latter is a typical feature of terminally differentiated effector memory $\gamma\delta$ T cell subsets,⁶ and both populations proliferated in response to anti-CD3/CD28 and anti-TCR $\gamma\delta$ mAb. Moreover, CD27^{lo/neg} cells contained granzyme A, B and perforin in contrast to CD27^{hi} cells and expressed CX3CR1. The overall analysis showed that V δ 1 clonal expansion was accompanied by a phenotypic and functional transition: of note, cord blood and adult V δ 1T cells with an unfocused TCR repertoire had a naive phenotype and did not express cytotoxic molecules, whereas clonally expanded V δ 1 populations were preferentially effector cells equipped with cytotoxic activity.

Collectively, these findings reveal a fundamentally adaptive behavior for V δ 1T cells, which is likely governed by the TCR, and strongly support a model involving the clonal selection of naive V δ 1T cells expressing TCRs enabling responses to yet-unknown antigens, accompanied by differentiation to a terminally differentiated effector memory phenotype. These authors argue against the idea that V δ 1 clonotypic focusing merely reflects an immunological imprint of past challenges and instead are more suggestive of a long-lived, highly specific, functional $\gamma\delta$ T-cell memory that enables augmented responses to recurrent challenges, akin to classical immunological memory, although importantly, not MHC restricted.

This model shares several key tenets with classical adaptive immunity but differs critically by being MHC-unrestricted, and it represents an unconventional mode of adaptive immune surveillance. Thus, this study presents many questions. Although the identity of the forces underlying V δ 1 TCR repertoire focusing is unknown, it might include microbial antigens and/or self-molecules.⁷ Furthermore, although the private TCR repertoires may reflect responses restricted to each individual, they do not formally exclude the likelihood of the degenerate recognition of conserved ligands by diverse TCRs.

CMV infection, which has been strongly associated with V δ 2⁻ T-cell responses,^{8,9} is not relevant to the data

of Davey and colleagues, since CMV-seronegative individuals also exhibited extreme clonotypic focusing. Additionally, it is important to determine why ~30% of the adults in the study of Davey and colleagues retain a largely unfocused, naive V δ 1 repertoire.

Moreover, the study of Davey and colleagues exclusively analyzed V δ 1⁺ T cells in the peripheral blood. No evidence on tissue-resident V δ 1⁺ T cells has been reported, although these cells represent a majority of the $\gamma\delta$ T cell population.¹⁰ This finding is important because residence in a non-lymphoid tissue, regardless of whether the tissue is normal or has undergone tumor transformation, serves as a major determinant of the phenotypic and functional characteristics of tissue-resident V δ 1 and V δ 2T cells (Meraviglia *et al.*, unpublished results). Because relatively little is known about human tissue-resident $\gamma\delta$ T cells, sequencing the TCR repertoire of cells isolated from several tissues is therefore necessary to better increase the current knowledge of the selection of the $\gamma\delta$ TCR repertoire and to determine the nature and mode of antigen recognition and the role of $\gamma\delta$ T cells in tissues. These aspects may be translationally

relevant and may provide novel therapeutic avenues in anti-tumor immune responses.^{11–13}

CONFLICT OF INTEREST

The authors declare no conflict of interest.

ACKNOWLEDGEMENTS

This work was supported by grants from the Ministry of Health "Ricerca Finalizzata 2007" to FD.

- 1 Bonneville M, O'Brien RL, Born WK. $\gamma\delta$ T cell effector functions: a blend of innate programming and acquired plasticity. *Nat Rev Immunol* 2010; **10**: 467–478.
- 2 Davey MS, Willcox CR, Joyce SP, Ladell K, Kasatskaya SA, McLaren JE *et al.* Clonal selection in the human V δ 1T cell repertoire indicates $\gamma\delta$ TCR-dependent adaptive immune surveillance. *Nat Commun* 2017; **8**: 14760.
- 3 Dieli F, Poccia F, Lipp M, Sireci G, Caccamo N, Di Sano C *et al.* Differentiation of effector/memory V δ 2T cells and migratory routes in lymph nodes or inflammatory sites. *J Exp Med* 2003; **198**: 391–397.
- 4 Sherwood AM, Desmarais C, Livingston RJ, Andriesen J, Haussler M, Carlson CS *et al.* Deep sequencing of the human TCR γ and TCR β repertoires provides evidence that TCR β rearranges after $\alpha\beta$, $\gamma\delta$ T-cell commitment. *Sci Transl Med* 2011; **3**: 90ra61.
- 5 Dimova T, Brouwer M, Gosselin F, Tassignon J, Leo O, Donner C *et al.* Effector V γ 9V δ 2T cells dominate the human fetal $\gamma\delta$ T-cell repertoire. *Proc Natl Acad Sci USA* 2015; **112**: E556–E565.
- 6 Caccamo N, Meraviglia S, Ferlazzo V, Angelini D, Borsellino G, Poccia F *et al.* Differential requirements for antigen or homeostatic cytokines for proliferation and differentiation of human V γ 9V δ 2 naive, memory and effector T cell subsets. *Eur J Immunol* 2005; **35**: 1764–1772.
- 7 Halary F, Pitard V, Dlubek D, Krzysiek R, de la Salle H, Merville P *et al.* Shared reactivity of V δ 2⁻ $\gamma\delta$ T cells against cytomegalovirus-infected cells and tumor intestinal epithelial cells. *J Exp Med* 2005; **201**: 1567–1578.
- 8 Déchanet J, Merville P, Lim A, Retière C, Pitard V, Lafarge X *et al.* Implication of $\gamma\delta$ T cells in the human immune response to cytomegalovirus. *J Clin Invest* 1999; **103**: 1437–1449.
- 9 Pitard V, Roumanes D, Lafarge X, Couzi L, Garrigue I, Lafon ME *et al.* Long-term expansion of effector/memory V δ 2⁻ $\gamma\delta$ T cells is a specific blood signature of CMV infection. *Blood* 2008; **112**: 1317–1324.
- 10 Hayday AC. $\gamma\delta$ T cells and the lymphoid stress-surveillance response. *Immunity* 2009; **31**: 184–196.
- 11 Silva-Santos B, Serre K, Norell H. $\gamma\delta$ T cells in cancer. *Nat Rev Immunol* 2015; **15**: 683–691.
- 12 Lo Presti E, Dieli F, Meraviglia S. Tumor-infiltrating $\gamma\delta$ T lymphocytes: pathogenic role, clinical significance, and differential programming in the tumor microenvironment. *Front Immunol* 2014; **5**: 607.
- 13 Wu D, Wu P, Qiu F, Wei Q, Huang J. Human $\gamma\delta$ T-cell subsets and their involvement in tumor immunity. *Cell Mol Immunol* 2017; **14**: 245–253.